PPD Aktie

PPD Rule of 40

Delisted·9. dec. 2021

Rule of 40 for PPD (PPD) pr. 15. aug. 2026 er 27,02 %. I foregående år var Rule of 40 16,73 % — en ændring på 61,52 % (højere).

Rule of 40

27,02 %

YoY

61,52%

Senest opdateret:

Rule of 40 for PPD er 2026 27,02 % . Rule of 40 for PPD var 2025 16,73 % . Det falder dermed med 61,52% højere sammenlignet med året før.
Access this data via the Eulerpool API

PPD Aktieanalyse

Hvad laver PPD? PPD Inc is a global company for medical research and services that was founded in 1985 and is headquartered in Wilmington, North Carolina, USA. The company is known for its ability to conduct clinical trials and develop research programs for the biopharmaceutical and medical industry. PPD is a leading provider of comprehensive, integrated services for phases I-IV of clinical research, from non-interventional studies to contract research for pharmaceutical and biotech clients. PPD's business model is based on three key pillars to provide customers with a broad portfolio of services: the first pillar is comprehensive clinical research required for drug registration with regulatory authorities, the second pillar focuses on providing research-based data and analytical methods to facilitate decision-making and risk assessment in the healthcare sector, and the third pillar encompasses extensive laboratory analyses and diagnostic tests to improve patient health and support research efforts. PPD has multiple divisions focused on specific markets and customers. The Clinical Trials division offers services for drug development up to approval by regulatory authorities, including the setup and monitoring of clinical trials and statistical analysis of test results. The Data Management division provides data capture and management solutions for clinical trials to ensure high data quality and compliance with regulations. The Medical Monitoring division offers medical consultation and monitoring during clinical trials. PPD also has a division for Real World Evidence studies, which collects data from routine clinical practice to assess the safety and efficacy of drugs. PPD has made some important acquisitions in the past to strengthen its presence in the industry. In 2011, PPD was acquired by private equity firms Carlyle Group and Hellman & Friedman, becoming a private company. In 2020, PPD went public. In 2018, PPD acquired Evidera, a company specializing in clinical epidemiology and outcomes research. In 2019, PPD acquired Q-Squared Solutions, expanding its extensive laboratory analysis and diagnostic testing capabilities. PPD's offerings include a wide range of products and services, including unique planning and implementation solutions that enable efficient conduct of clinical trials. These solutions also include electronic data capture and management systems, as well as statistical analysis tools. PPD also offers specialized services, such as training programs for clinical investigators and staff. PPD aims to enable safe, faster, and cost-effective drug development through clinical research. In the future, PPD will continue to expand its business model and services to meet the needs of its customers in the changing industry and support innovative research programs. PPD er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om PPD aktie

Rule of 40 for PPD er 27,02 % i 2026.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Rule of 40 PPD siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

Rule of 40 siger, at en virksomheds omsætningsvækstrate plus fortjenstmargin skal overstige 40%. Det bruges bredt til at vurdere SaaS- og højtvækstvirksomheder.

Access this data via the Eulerpool API

Kvalitet — PPD

Alle nøgletal — PPD